

AVI BIOPHARMA INC  
Form SC 13G/A  
February 12, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE  
COMMISSION**  
Washington, D.C. 20549  
**SCHEDULE 13G**

OMB APPROVAL  
OMB Number:  
3235-0145

Expires:  
February 28, 2009  
Estimated average burden  
hours per response. . 10.4

**Under the Securities Exchange Act of 1934  
(Amendment No. 4)\***

**AVI BioPharma, Inc.**

(Name of Issuer)

**Common Stock, \$.0001 par value**

(Title of Class of Securities)

**637184 10 8**

(CUSIP Number)

**01/01/07**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: AVI BIOPHARMA INC - Form SC 13G/A

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

---

CUSIP No. 637184 10 8

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)  
 SuperGen, Inc.  
 91-1841574

2. Check the Appropriate Box if a Member of a Group (See Instructions)  
 (a)   
 (b)

3. SEC Use Only

4. Citizenship or Place of Organization  
 Delaware

Number of Shares Beneficially Owned by Each Reporting Person With	5.	Sole Voting Power 2,384,211
	6.	Shared Voting Power 0
	7.	Sole Dispositive Power 2,384,211
	8.	Shared Dispositive Power 0

9. Aggregate Amount Beneficially Owned by Each Reporting Person  
 2,384,211

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)  
 4.5%

12. Type of Reporting Person (See Instructions)  
 CO

Edgar Filing: AVI BIOPHARMA INC - Form SC 13G/A

Item 1.

- (a) Name of Issuer  
AVI BioPharma, Inc.
- (b) Address of Issuer's Principal Executive Offices  
One S.W. Columbia Street, Suite 1105, Portland, Oregon 97258

Item 2.

- (a) Name of Person Filing  
SuperGen, Inc.
- (b) Address of Principal Business Office or, if none, Residence  
4140 Dublin Boulevard, Suite 200, Dublin, CA 94568
- (c) Citizenship  
Delaware
- (d) Title of Class of Securities  
Common Stock, \$.0001 par value
- (e) CUSIP Number  
637184 10 8

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:  
Not applicable.

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
- (e)  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned:  
  
2,384,211 shares
- (b) Percent of class:  
  
4.5%, based on 52,971,402 outstanding shares of Common Stock of the Issuer as of November 3, 2006, as reported in the Issuer's last Quarterly Report on Form 10-Q filed on November 9, 2006.
- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or to direct the vote
  - (ii) 2,384,211 shares  
Shared power to vote or to direct the vote
  - (iii) 0  
Sole power to dispose or to direct the disposition of
  - (iv) 2,384,211 shares  
Shared power to dispose or to direct the disposition of

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

Item 6. Ownership of More than Five Percent on Behalf of Another Person  
Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person  
Not applicable.

Item 8. Identification and Classification of Members of the Group  
Not applicable.

Item 9. Notice of Dissolution of Group  
Not applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

**Signature**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

02/12/07

Date

/S/ MICHAEL MOLKENTIN

Signature

Michael Molquentin, Chief Financial Officer

Name/Title

5

---